- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.01. | HEXIMA LIMITED: Business Activity Statement & Appendix 4C - Dec-2025 | - | ASX | ||
| 22.01. | HEXIMA LIMITED: Long Term Suspended Entities | 1 | ASX | ||
| 27.11.25 | HEXIMA LIMITED: AGM - Results of Meeting | - | ASX | ||
| 27.11.25 | HEXIMA LIMITED: AGM - Chair's Address - The Path Forward | 1 | ASX | ||
| 31.10.25 | HEXIMA LIMITED: Business Activity Statement & Appendix 4C - Sep-2025 Qtr | - | ASX | ||
| HEXIMA Aktie jetzt für 0€ handeln | |||||
| 24.10.25 | HEXIMA LIMITED: Annual General Meeting & Proxy Form | - | ASX | ||
| 15.10.25 | HEXIMA LIMITED: Long Term Suspended Entities | - | ASX | ||
| 19.09.25 | HEXIMA LIMITED: Annual General Meeting & Director Nomination | - | ASX | ||
| 29.08.25 | HEXIMA LIMITED: 2025 Annual Report | - | ASX | ||
| 29.08.25 | HEXIMA LIMITED: Appendix 4G | - | ASX | ||
| 29.08.25 | HEXIMA LIMITED: Appendix 4E | - | ASX |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,475 | -0,84 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Umsatz und Ergebnis des vierten Quartals hätten die Erwartungen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,82 | +0,14 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 73,21 | -9,91 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| RECURSION PHARMACEUTICALS | 3,565 | -8,59 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 305,95 | +0,86 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 16,550 | -9,22 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 | - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 75,82 | -2,42 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| ERASCA | 11,885 | +12,28 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| LIMINATUS PHARMA | 2,030 | +40,97 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| ARCELLX | 66,94 | -3,52 % | Arcellx reports D-Domain binder shows no tonic signaling in CAR T therapy | ||
| SUMMIT THERAPEUTICS | 13,860 | -3,95 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ALUMIS | 26,340 | -0,04 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| BIONTECH | 89,80 | -2,60 % | BioNTech- und Nvidia-Aktien verkauft, Medline und Alphabet rein: Erste 13F-Filings sind da! | Der britische Vermögensverwalter Baillie Gifford hat als einer der ersten sein 13F-Filing für das 4. Quartal abgegeben. Unter den großen Namen im Portfolio gibt es ein paar spannende Veränderungen.... ► Artikel lesen | |
| IMMUNOVANT | 24,060 | -4,35 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| CG ONCOLOGY | 49,210 | -5,26 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen |
HEXIMA LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEXIMA LIMITED finden Sie auf Wallstreet Online.